James B. Breitmeyer - Jan 20, 2022 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Chief Executive Officer, Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Jan 20, 2022
Transactions value $
$0
Form type
4
Date filed
1/24/2022, 03:14 PM
Previous filing
Jan 5, 2022
Next filing
Jan 31, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONCT Stock Option Award $0 +637K $0.00 637K Jan 20, 2022 Common Stock 637K $1.94 Direct F1
transaction ONCT Stock Option Award $0 +165K $0.00 165K Jan 20, 2022 Common Stock 165K $1.94 By Spouse F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in 36 equal monthly installments over the three-year period thereafter, subject to the Recipient's continued employment or service with the Issuer on each such date.